Getagraph.com logo
S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

Sanntidsoppdatering for Autolus Therapeutics PLC [AUTL]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
BUY
71.43%
return 14.35%
SELL
28.57%
return 1.74%
Sist oppdatert3 mai 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

1.95% $ 4.19

SELG 115790 min ago

@ $7.30

Utstedt: 14 feb 2024 @ 21:45

Avkastning: -42.56%

Forrige signal: feb 14 - 18:33

Forrige signal: Kjøp

Avkastning: 4.66 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Profile picture for Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma...

Stats
Dagens volum 1.94M
Gjennomsnittsvolum 1.85M
Markedsverdi 729.48M
EPS $0 ( 2024-03-14 )
Neste inntjeningsdato ( $-0.100 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.49
ATR14 $0.0100 (0.24%)

Volum Korrelasjon

Lang: -0.01 (neutral)
Kort: 0.53 (weak)
Signal:(55.928) Neutral

Autolus Therapeutics PLC Korrelasjon

10 Mest positive korrelasjoner
PBTS0.943
OP0.94
FLGC0.938
FNCH0.922
NNOX0.919
ALBO0.916
WKSP0.915
POWL0.912
NBSE0.91
DMRC0.907
10 Mest negative korrelasjoner
PRAA-0.919
RMRM-0.908
DTEA-0.879
AVID-0.875
FCCO-0.873
PINC-0.863
IEP-0.856
PEBK-0.854
PARA-0.853
TUEM-0.851

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Autolus Therapeutics PLC Korrelasjon - Valuta/Råvare

The country flag -0.60
( weak negative )
The country flag -0.39
( neutral )
The country flag 0.00
( neutral )
The country flag -0.79
( moderate negative )
The country flag 0.73
( moderate )

Autolus Therapeutics PLC Økonomi

Annual 2023
Omsetning: $1.70M
Bruttogevinst: $-4.87M (-286.63 %)
EPS: $-1.200
FY 2023
Omsetning: $1.70M
Bruttogevinst: $-4.87M (-286.63 %)
EPS: $-1.200
FY 2022
Omsetning: $6.19M
Bruttogevinst: $-131.03M (-2 115.37 %)
EPS: $-1.570
FY 2021
Omsetning: $2.33M
Bruttogevinst: $0.00 (0.00 %)
EPS: $-1.970

Financial Reports:

No articles found.

Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.